United States — Food and Drug Administration & Paragon Therapeutics

United States — Food and Drug Administration: The United States — Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee is convening a meeting to review Paragon Therapeutics' Biologics License Application for Deramiocel, which is a critical step in the regulatory approval process for the drug.

Paragon Therapeutics: Paragon Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the United States — Food and Drug Administration will convene a meeting to discuss its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. This is a significant step towards potential market approval for their lead product candidate.

United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.

Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.

United States — Food and Drug Administration: The FDA extended the PDUFA date to review the major amendment, citing unmet medical need. This action directly impacts Capricor's regulatory timeline.

Paragon Therapeutics: Capricor is the sponsor of the BLA and the primary subject of the FDA's regulatory decision. The extension delays potential approval but the company remains optimistic about the data supporting the refined indication.

United States — Food and Drug Administration: The FDA published briefing documents critical of Capricor's statistical analysis plan and raised concerns about the benefit-risk profile of Deramiocel. This regulatory action triggered the stock drop and the subsequent lawsuit, and it may influence the advisory committee's decision on the BLA.

Paragon Therapeutics: Capricor is the defendant in the class action lawsuit and the subject of FDA criticism regarding its statistical analysis plan. The company's stock plummeted 64% following the FDA's briefing documents, and it faces potential legal liabilities and regulatory hurdles for its lead product candidate.

United States — Food and Drug Administration: The FDA is reviewing the U.S. NDA for NCX 470, with approval expected in summer 2027. Its decision is critical for the drug's launch in the U.S.

Paragon Therapeutics: Ocumension is the exclusive licensee in China and submitted the NDA. It has already invested €18 million in license fees and contributed to trial costs, positioning itself for a commercial launch and potential revenue from NCX 470 sales.

United States — Food and Drug Administration: Approved Phase 2 trial protocol for MTX652.

Paragon Therapeutics: Divests MTX652 to focus on CNS pipeline, receives up to $292M in payments.

Paragon Therapeutics: Paragon Therapeutics is facing a class action lawsuit for allegedly providing misleading statements regarding its lead cell therapy candidate drug, deramiocel, which led to a significant stock price decline after the United States — Food and Drug Administration denied its Biologics License Application.

Paragon Therapeutics: Paragon Therapeutics, NicOx's exclusive licensee in China, received positive pre-submission regulatory feedback for NCX 470, allowing them to proceed with the New Drug Application submission in China. This is a significant step towards commercializing the drug in their licensed territories.